Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16

What: Monopar Therapeutics reported a GAAP EPS of -$0.61, missing the expected EPS by $0.16.
Why: The company's financial performance was impacted by increased research and development expenses.
Signal: The miss in EPS indicates a potential decline in investor confidence.
Target: Analysts expect Monopar Therapeutics to revise its guidance downward in the coming quarters.
Risk: The company's stock price may experience significant volatility in the short term.